Возможности использования омега-3 полиненасыщенных жирных кислот при сердечных аритмиях


Моисеев С.В.

ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития, Москва. МГУ им. М.В. Ломоносова, Москва.
Существующие проблемы антиаритмической терапии (ограниченная эффективность, аритмогенное действие, экстракардиальные побочные эффекты и др.) диктуют необходимость поиска новых терапевтических подходов. С этой точки зрения большой интерес представляет изучение возможностей применения при аритмиях ?-3 полиненасыщенных жирных кислот (ПНЖК), результаты которого представлены в настоящем обзоре. Наибольшего антиаритмического эффекта при лечении ?-3 ПНЖК, по-видимому, следует ожидать у пациентов с ИБС и желудочковыми нарушениями ритма без выраженных структурных изменений в миокарде, при нормальной или умеренно сниженной фракции выброса левого желудочка. В двух крупных рандомизированных контролируемых исследованиях установлена эффективность длительной терапии ?-3 ПНЖК 90 % в дозе 1 г/сут в профилактике неблагоприятных сердечно-сосудистых исходов у пациентов с инфарктом миокарда и сердечной недостаточностью, нередко ассоциирующимися с сердечными аритмиями.

Литература


1. ACC/AHA/ESC 2006 Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2006;27:2099–140.


2. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324(12):781–88.


3. Epstein A, DiMarco J, Ellenbogen K,et al. ACC/ AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51(21):1–62.


4. Сonnolly S, Hallstrom A, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Eur Heart J 2000;21: 2071–78.


5. Reiffel J, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006; 98: 50–60.


6. Kang J, Leaf A. Evidence that free polyunsaturated fatty acids modify Na+ channels by directly binding to the channel proteins. Proc Natl Acad Sci USA 1996;93:3542–46.


7. Xiao Y., Gomez A., Morgan J. et al. Supression of voltage-gated L-type Ca2 + currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997;94:4182–87.


8. Garrat J, McEnvoy M, Owen D. Blocade of two voltage-dependent potassium channels, mKv 1.1 and mKv 1.2, by docosahexanoic acid. Eur J Pharmacol 1996;314:393–96.


9. Li GR, Sun HY, Zhang XH, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K1currents and Na1current in human atrial myocytes. Cardiovascular Res 2009;81:286–93.


10. Leaf A, Kang J. Prevention of cardiac sudden death by n-3 fatty acids: a review of the evidence. J Intern Med 1996;240:5–12.


11. Leaf A, Xiao Y, Kang J, et al. Prevention of sudden cardiac death by omega-3 polyunsaturated fatty acids. Pharmacol Ther 2003;98:355–77.


12. McLennan P, Bridle T, Abeywardena M, et al. Comparative efficacy of ω-3 and ω-6 polyunsaturated fatty acids in modulating ventricular fibrillation threshold in marmoset monkeys. Am J Clin Nutr 1993;58:666–69.


13. Billman G, Kang J, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999;99:2452–57.


14. Pepe S, McLennan P. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 1996;126:34–42.


15. Curtis B, O’Keefe J. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. Mayo Clin Proc 2002;77:45–54.


16. Christensen J, Gustenhoff P, Korup E, et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. Br Med J 1996;312(7032):677–78.


17. O’Keefe J, Abuissa H, Sastre A, et al. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. Am J Cardiol 2006;97:1127–30.


18. Mozaffarian D, Prineas R, Stein P, et al. Dietary fish and ω-3 fatty acid intake and cardiac electrocardiographic parameters in humans. JAmCollCardiol 2006;48:478–84.


19. Царегородцев Д.А., Гавва Е.М., Сулимов В.А. Омега-3-полиненасыщенные жирные кислоты в лечении заболеваний сердечно-сосудистой системы // Кардиология 2010. № 8. C. 47–53.


20. Singer P, Wirth M. Can omega-3 polyunsaturated fatty acids reduce cardiac arrhythmias? Results of a clinical trial. Prostaglandins Leukot Essent Fatty Acids 2004;71:153–59.


21. Sellmayer A, Witzgall H, Lorenz R, et al. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 1995;76:974–77.


22. Biscione F, Totteri A, De Vita A, et al. Effect of omega-3 fatty acids on the prevention of atrial arrhythmias [in Italian]. Ital Heart J Suppl 2005;6:53–59.


23. Geelen A, Brouwer I, Schouten E, et al. Effects of omega-3 fatty acids from fish on premature ventricular complexes and heart rate in humans. Am J Clin Nutr 2005;81:416–20.


24. Нифонтов Е.М., Шихалиев Д.Р., Богачев М.И. и др. Антиаритмическая эффективность омега-3 полиненасыщенных жирных кислот у больных стабильной ишемической болезнью сердца с желудочковыми нарушениями ритма // Кардиология 2010. C. 12.


25. Raitt M, Connor W, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884–91.


26. Leaf A, Albert C, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil ω-3 fatty acid intake. Circulation 2005;112:2762–768.


27. Brower I, Zock P, Camm A, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613–19.


28. Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45:1723–28.


29. Панов А.В., Татарский Б.А., Гордеев М.Л., Нильк Р.Я. Омега-3-полиненасыщенные жирные кислоты в профилактике фибрилляции предсердий после хирургической реваскуляризации миокарда // Рациональная фармакотерапия в кардиологии 2008. № 3. С. 26–30.


30. Mariscalco G, Sarzi Braga S, Banach M, et al. Preoperative ω-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology 2010;61(7):643–50.


31. Saravanan P, Bridgewater B, West A, et al. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, doubleblind, placebocontrolled clinical trial. Circ Arrhythm Electrophysiol 2009;3:46–53.


32. Heidarsdottir R, Arnar D, Skuladottir G, et al. Does treatment with n-3 polyunsaturated fatty acids prevent atrial fibrillation after open heart surgery? Europace 2010;12:356–63.


33. Nodari S, Manerba A, Madureri A, et al. Effects of Polyunsaturated Fatty Acids ω-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion. EurHeartJ2006;27:887.


34. Антонченко И.В., Татарский Б.А., Родионов В.А. и др. Использование омега-3 полиненасыщенных жирных кислот при лечении пароксизмальных форм фибрилляции предсердий // Вестник аритмологии 2008. № 53.


35. GISSI-Prevenzione Investigators. Dietary supplementation with ω-3 polyunsaturated fatty acids and vitamin E after myocardial infraction: results of the GISSIPrevenzione trial. Lancet 1999;354:447–55.


36. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction. Circulation 2002;105:1897–903.


37. Marchioli R. Oral communication. ESC Congress 2002, Berlin. August 31 2002.


38. GISSI-HF investigators. Effect of ω-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet 2008;372:1223–30.


39. Ghio S, Scelsi L, Latini R, et al. Effects of ω-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 2010.


40. Gheorghiade M. Effects of ω-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. Heart Failure Society of America 2010 Scientific Meeting; September 15, 2010; San Diego, CA. Late-breaking clinical trials II


41. Carroll D, Roth M. Evidence for the cardioprotective effects of omega-3 fatty acids. Ann Pharmacother 2002;36:1950–56.


42. Mozaffarian D, Lemaitre R, Kuller L, et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003;107:1372–77.


43. Kromhout D, Giltay E, Geleijnse J. ω-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015–202.


44. Nair S, Leitch J, Falconer J, et al. Prevention of cardiac arrhythmia by dietary (ω-3) polyunsaturated fatty acids and their mechanism of action. J Nutr 1997;127:383–93.


Похожие статьи


Бионика Медиа